ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2217

Adherence to Drug Therapy in Patients with Fibromyalgia

Guillermo Bennasar Sr.1, Anastasia Secco2 and Marta Mamani3, 1Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 2Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 3Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: As in other chronic diseases, adherence to the treatment regimen of patients with fibromyalgia (FM) is low (between 30 and 80%), depending on the definition of adherence and the methodology used to measure it. This study aims to determine the level of adherence to drug therapy in patients with FM and identify factors associated with non-compliance to therapy.

Methods: an analytical and cross-sectional study was conducted. Patients with FM were included considering the classification criteria (ACR 1990) for both those who were receiving drugs for the treatment for their disease and those who attended the outpatient clinic. For the assessment of adherence, the questionnaires CQR (Compliance Questionnaire on Rheumatology) were used, to assess anxiety GAD-7 (Generalized Anxiety Disorder), to assess depression PHQ-9 (Patient Helth Questionnaire) and to assess the impact disease of the S-FIQ (Spanish Fibromyalgia Impact Questionnaire) were used.

Results: 78 patients were surveyed (70 women). The mean age was 47,3 years. 41% (32 patients) were adherent (CQR> 80). 41% (19) of the nonadherent had severe depression according to the PHQ-9 vs 6% (2) of those which if adhered. 67% (31) of the nonadherent had severe anxiety by questionnaire GAD-7 vs the 16% (5) of which adhered. It was also observed that 87% (40) of nonadherent had low quality of life measured by the S-FIQ (S-FIQ >50%) questionnaire vs. a 50% (16) of the adherent members who had good quality of life. The three cases showed a statistically significant association with non-adherence to drug treatment.

Conclusion: it was observed that less than half of FM patients were adherent to drug treatment. Factors associated with nonadherence were depression, anxiety and reduced quality of life.


Disclosure: G. Bennasar Sr., None; A. Secco, None; M. Mamani, None.

To cite this abstract in AMA style:

Bennasar G Sr., Secco A, Mamani M. Adherence to Drug Therapy in Patients with Fibromyalgia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/adherence-to-drug-therapy-in-patients-with-fibromyalgia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-drug-therapy-in-patients-with-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology